PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 78 filers reported holding PROTAGONIST THERAPEUTICS INC in Q1 2020. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2023 | $345,000 | +110.4% | 15,014 | 0.0% | 0.00% | 0.0% |
Q4 2022 | $164,000 | +5.8% | 15,014 | -18.5% | 0.00% | 0.0% |
Q3 2022 | $155,000 | +638.1% | 18,422 | +526.0% | 0.00% | – |
Q1 2020 | $21,000 | +5.0% | 2,943 | +1.5% | 0.00% | – |
Q4 2019 | $20,000 | – | 2,900 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
JOHNSON & JOHNSON | 2,449,183 | $26,721 | 7.77% |
Bain Capital Life Sciences Investors, LLC | 2,364,410 | $25,796 | 2.88% |
Sio Capital Management, LLC | 434,635 | $4,741,868 | 1.75% |
Tri Locum Partners LP | 199,500 | $2,177,000 | 0.88% |
Kynam Capital Management, LP | 520,922 | $5,683,259 | 0.87% |
RTW INVESTMENTS, LP | 3,591,986 | $39,188,567 | 0.80% |
Madison Avenue Partners, LP | 406,593 | $4,435,930 | 0.79% |
Deep Track Capital, LP | 871,493 | $9,507,989 | 0.40% |
Soleus Capital Management, L.P. | 236,000 | $2,574,760 | 0.37% |
BRAIDWELL LP | 927,800 | $10,122,298 | 0.34% |